Literature DB >> 19667021

Magnetic resonance evidence of cortical onset of multiple sclerosis.

M Calabrese1, P Gallo.   

Abstract

BACKGROUND: Despite clinical symptoms and signs of central nervous system dysfunction, conventional magnetic resonance imaging (MRI) of the brain and spinal cord may appear normal in multiple sclerosis (MS) at clinical onset.
OBJECTIVE: To demonstrate cortical pathology, namely the presence of cortical lesions (CLs) in patients with symptoms/signs suggestive of MS but having normal appearing white matter (WM) on MRI.
METHODS: CLs were disclosed by double inversion recovery (DIR) MRI sequence. The final diagnosis of MS was achieved by the demonstration of the dissemination in space and time of WM lesions, and the absence of a better explanation of symptoms/signs, according to the established international diagnostic criteria.
RESULTS: We describe four patients with MS, in which CLs were observed by DIR months/years before the MRI evidence of inflammatory lesions in the WM.
INTERPRETATION: We suggest that, at least in some patients with MS, the pathological process underlying MS starts in the cortex. DIR sequence should be included in the MRI examination of suspected patients with MS with normal conventional MRI sequences at clinical onset. CLs should be evaluated for their inclusion in the MRI diagnostic criteria for MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667021     DOI: 10.1177/1352458509106510

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  32 in total

1.  Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.

Authors:  F Rinaldi; M Calabrese; D Seppi; M Puthenparampil; P Perini; P Gallo
Journal:  Neurol Sci       Date:  2011-01       Impact factor: 3.307

2.  Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population.

Authors:  M Calabrese; D Seppi; C Romualdi; F Rinaldi; S Alessio; P Perini; P Gallo
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

Review 3.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

4.  FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection.

Authors:  V Wiggermann; E Hernández-Torres; A Traboulsee; D K B Li; A Rauscher
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-08       Impact factor: 3.825

Review 5.  Cortical lesions in multiple sclerosis.

Authors:  Massimiliano Calabrese; Massimo Filippi; Paolo Gallo
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

6.  A case of multiple sclerosis presenting with inflammatory cortical demyelination.

Authors:  B F Gh Popescu; R F Bunyan; J E Parisi; R M Ransohoff; C F Lucchinetti
Journal:  Neurology       Date:  2011-05-17       Impact factor: 9.910

Review 7.  Grey matter damage in multiple sclerosis: a pathology perspective.

Authors:  Roel Klaver; Helga E De Vries; Geert J Schenk; Jeroen J G Geurts
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 8.  Grey matter lesions in MS: from histology to clinical implications.

Authors:  Massimiliano Calabrese; Alice Favaretto; Valeria Martini; Paolo Gallo
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

9.  Regional Frontal Perfusion Deficits in Relapsing-Remitting Multiple Sclerosis with Cognitive Decline.

Authors:  R Vitorino; S-P Hojjat; C G Cantrell; A Feinstein; L Zhang; L Lee; P O'Connor; T J Carroll; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2016-05-19       Impact factor: 3.825

10.  Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR.

Authors:  I D Kilsdonk; W L de Graaf; A Lopez Soriano; J J Zwanenburg; F Visser; J P A Kuijer; J J G Geurts; P J W Pouwels; C H Polman; J A Castelijns; P R Luijten; F Barkhof; M P Wattjes
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.